Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET -Altered Solid Tumors: Analysis of the RETgistry Global Consortium
Authors:
- Sarah WalianySWSarah Waliany
- Alissa J. CooperACAlissa J. Cooper
- Stephen V. LiuStephen V. Liu
- Oliver GautschiOGOliver Gautschi
- Julia K. RotowJRJulia K. Rotow
- Katherine Emilie Rhoades SmithKSKatherine Emilie Rhoades Smith
- Urs M. WeberUWUrs M. Weber
- Dae Ho LeeDLDae Ho Lee
- Herbert H.F. LoongHLHerbert H.F. Loong
- Jyoti D. PatelJPJyoti D. Patel
- Nathan A. PennellNPNathan A. Pennell
- Misako NagasakaMNMisako Nagasaka
- 15 January 2026
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (6) , 1157-1168
Abstract
Purpose: Rearranged during transfection (RET) alterations are oncogenic drivers across solid tumors. Selective RET inhibitors (SRI) selpercatinib and pralsetinib have transformed outcomes for patients with RET-altered malignancies. Limited knowledge exists on genomic mechanisms of resistance to SRI. Experimental Design: We established “RETgistry,” a global consortium of patients with advanced RET-altered solid tumors who received SRI and underwent postprogression tissue or plasma biopsies assessed by next-generation sequencing. Frequencies of secondary RET resistance mutations and acquired non-RET gene alterations were determined. Progression-free survival (PFS) and time to treatment discontinuation (TTD) on first SRI were estimated with the Kaplan–Meier method. Results: RETgistry included 109 patients with RET-altered advanced solid tumors (lung, n = 94; thyroid, n = 15) who underwent 143 post-SRI progression biopsies (tissue, 91; plasma, 52). The median PFS and TTD were 13.9 months [95% confidence interval (CI), 10.1–16.6] and 17.3 months (95% CI, 14–20.2), respectively. Secondary RET mutations were detected in 20 (14%) biopsies [lung cancer, 15 (12.4%) and thyroid carcinoma, 5 (22.7%)]. Common acquired off-target alterations involved MET (18.2%; amplification, 15%), TP53 (8.2%), APC (7.6%), KRAS (7.1%), KEAP1 (5.9%), and CDKN2A/B (5.3%). MET alterations were enriched in post-SRI versus pre-SRI specimens (full cohort, 17.6% vs. 2.0%, P = 0.022; lung cancer, 19.1% vs. 2.1%, P = 0.022). Conclusions: The prevalence of secondary RET mutations after SRI was low, underscoring a greater role for off-target resistance. Recurrent acquired alterations involving tumor suppressor genes or upstream regulators of MAPK and PI3K pathways were identified, most commonly MET amplification. Continued efforts to characterize SRI resistance biology are critical to guide the development of novel therapeutic strategies.Keywords
All Related Versions
Funding Information
- National Cancer Institute (P50 CA265826)
- National Cancer Institute (P30 CA008748)
- National Cancer Institute (1R01CA251591001A1)
- National Cancer Institute (1R01CA273224-01)
- National Cancer Institute (1R01CA226864-01A1)
- National Cancer Institute (R21 CA251923)
- National Cancer Institute (R33 CA272271)
- National Cancer Institute (U24 CA283479)
- National Cancer Institute (UG1 CA232760)
- Mark Foundation For Cancer Research (ASPIRE Award)
- U.S. Department of War (Concept Award W81XWH-22-1-0021)
This publication has 53 references indexed in Scilit:
- Multiple Endocrine Neoplasia Type 2 and Familial Medullary Thyroid Carcinoma: An UpdateThe Journal of Clinical Endocrinology & Metabolism, 2013
- RET Fusions Define a Unique Molecular and Clinicopathologic Subtype of Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2012
- RET, ROS1 and ALK fusions in lung cancerNature Medicine, 2012
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR InhibitorsScience Translational Medicine, 2011
- Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLCCancer Cell, 2010
- New Mutations in the RET Protooncogene-L881V – Associated with Medullary Thyroid Carcinoma and -R770Q – in a Patient with Mixed Medullar/Follicular Thyroid TumourExperimental and Clinical Endocrinology & Diabetes, 2009
- RET tyrosine kinase signaling in development and cancerCytokine & Growth Factor Reviews, 2005
- Biochemical and biological responses induced by coupling of Gab1 to phosphatidylinositol 3-kinase in RET-expressing cellsBiochemical and Biophysical Research Communications, 2004
- Protein kinase Cα activation by RET: evidence for a negative feedback mechanism controlling RET tyrosine kinaseOncogene, 2003
- Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2ANature, 1993